UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CARDIOVASCULAR & METABOLIC

GE HealthCare

G

GE HealthCare

Cardiovascular & MetabolicChicago, United States
Visit Website

About GE HealthCare

GE HealthCare spun out of General Electric in January 2023 to become an independent, publicly traded medical technology company, bringing with it more than a century of imaging and diagnostics heritage. Listed on the Nasdaq under the ticker GEHC, the company operates across more than 160 countries, serving hospitals, imaging centres, and life-science laboratories worldwide.

Imaging & Diagnostics Portfolio

The company's core business centres on medical imaging systems, including MRI, CT, PET/CT, X-ray, and ultrasound platforms. Its portfolio spans everything from point-of-care ultrasound devices to large-bore scanners used in oncology and cardiology departments. GE HealthCare's Edison platform provides an open software ecosystem that allows AI-powered applications to be deployed directly on imaging hardware, enabling faster interpretation and workflow automation at the point of care.

Patient Care Solutions & Pharmaceutical Diagnostics

Beyond capital equipment, GE HealthCare supplies pharmaceutical diagnostics (contrast agents and radiopharmaceutical tracers), patient monitoring systems, and anaesthesia delivery products. Its pharmaceutical diagnostics division manufactures contrast media used in MRI and CT procedures globally, making it one of the largest producers in that segment. The company also provides service contracts, digital health software, and data analytics tools designed to improve operational efficiency in clinical environments.

Headquartered in Chicago, Illinois, GE HealthCare employs tens of thousands of people worldwide and maintains manufacturing and research facilities across North America, Europe, and Asia-Pacific. Its customer base includes academic medical centres, community hospitals, outpatient imaging networks, and pharmaceutical manufacturers conducting clinical research.

The company organises its business into four reporting segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, reflecting the breadth of its involvement across the care pathway from diagnosis through monitoring. Strategic priorities since independence have included expanding AI-enabled software revenue, growing its services business, and extending its presence in emerging markets.

Further information is available at gehealthcare.com.

Similar Companies

More in Cardiovascular & Metabolic

A

Albuquerque Clinical Trials

Dedicated entirely to Phase II-IV clinical trials, Albuquerque Clinical Trials has operated as a locally owned, independent research centre since 1988. Based in Albuquerque, New Mexico, the site conducts studies on behalf of pharmaceutical and biotechnology sponsors across a broad range of therapeutic areas. The facility's in-house team brings together board-certified physicians, a PharmD, certified study coordinators, licensed clinicians, regulatory specialists, recruitment professionals and data entry personnel. This integrated staffing model allows the centre to manage all phases of a trial from a single site, reducing sponsor coordination burden and supporting consistent data quality. The active study portfolio covers a diverse set of indications, including type I and type II diabetes, obesity-related conditions, weight loss, gout, heart failure prevention, systemic lupus erythematosus, coeliac disease, migraines, male incontinence, constipation and infectious disease, including a C. difficile vaccine programme. Birth control and menstrual migraine studies are also listed among current or recent therapeutic areas, reflecting the breadth of the clinical programme. The centre states its core commitments as exceeding sponsor expectations for dependability, human protection, subject enrolment and overall performance, with the broader aim of improving patient health through access to innovative therapies. Patient-facing infrastructure includes a dedicated sign-up pathway and a sponsor referral channel. Further information is available at abqct.com.

View profile
B

Boston Scientific

Boston Scientific pioneered the development of minimally invasive medical devices and has been transforming the way conditions are diagnosed and treated for more than four decades. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company has grown into one of the world's largest medical device manufacturers, listed on the New York Stock Exchange under the ticker BSX. Cardiology & Electrophysiology Cardiac care sits at the core of Boston Scientific's portfolio. The company is widely recognised for its electrophysiology technologies, including mapping and ablation systems used to treat cardiac arrhythmias, as well as transcatheter heart valves, stents, and heart failure management devices. Its WATCHMAN device, designed to reduce stroke risk in patients with non-valvular atrial fibrillation by closing the left atrial appendage, has become one of its most prominent commercial products globally. Endoscopy, Urology & Neuromodulation Beyond cardiology, Boston Scientific holds strong positions in endoscopy, offering a broad range of tools for gastrointestinal diagnosis and intervention, and in urology and pelvic health, where it provides stone management, benign prostatic hyperplasia treatment, and incontinence solutions. Its neuromodulation division manufactures spinal cord stimulation and deep brain stimulation systems, addressing chronic pain and movement disorders such as Parkinson's disease. The company operates across more than 100 countries, with a substantial manufacturing and research presence in the United States, Europe, and Asia. Boston Scientific employs tens of thousands of people worldwide and invests heavily in research and development each year, sustaining a pipeline that spans structural heart, peripheral interventions, oncology, and cardiac rhythm management. Acquisitions have been central to its growth strategy, with notable deals including the purchase of Guidant Corporation and, more recently, Silk Road Medical and Acotec Scientific, expanding its reach into carotid artery disease and peripheral vascular intervention respectively. Further information is available at bostonscientific.com.

View profile
A

Abbott

Abbott is one of the most broadly diversified healthcare companies in the world, operating across diagnostics, medical devices, nutritional products, and established pharmaceuticals. Founded in 1888 by physician Wallace Calvin Abbott in Chicago, the company has grown over more than a century into a global enterprise with operations in more than 160 countries and products used by hundreds of millions of people every day. Diagnostics & Point-of-Care Innovation Abbott's diagnostics division is among the largest in the industry, encompassing laboratory systems, rapid testing platforms, and molecular diagnostics. The company's point-of-care testing portfolio gained widespread recognition during the COVID-19 pandemic, when its BinaxNOW rapid antigen tests became one of the most widely deployed diagnostic tools globally. Its Alinity family of laboratory instruments serves hospitals and reference labs across multiple testing disciplines, including immunoassay, clinical chemistry, haematology, and molecular analysis. Cardiovascular & Neuromodulation Devices The medical devices segment, which Abbott significantly expanded through its 2017 acquisition of St. Jude Medical, covers cardiovascular and neuromodulation technologies. Products include electrophysiology catheters, cardiac rhythm management devices, structural heart solutions, and the Libre family of continuous glucose monitoring systems. FreeStyle Libre has become one of the most widely adopted continuous glucose monitors worldwide, transforming diabetes management for patients across dozens of markets. Abbott's nutrition business, operating under brands including Ensure and Similac, serves both adult and paediatric markets globally. Its established pharmaceuticals division focuses on branded generics, primarily serving emerging markets where access to quality medicines at affordable price points is a priority. Headquartered in Abbott Park, Illinois, Abbott is listed on the New York Stock Exchange under the ticker ABT and is a long-standing component of the S&P 500. The company's research and manufacturing footprint spans facilities across the United States, Europe, Asia-Pacific, and Latin America. Further information is available at abbott.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy